Advanced Organoids platform

AccelBio’s iPSC-based organoid platform leverages stem cell technology to create highly relevant, human-like in vitro models for drug discovery, disease modeling, and personalized medicine. These organoids are rapidly differentiated from pluripotent stem cells, offering a flexible and efficient approach to modeling human biology. Once established, organoids are robust and scalable, enabling large-scale genomic and drug screening efforts with high reproducibility. Modern genetic engineering tools can be applied to both induced pluripotent stem cells (iPSCs) and organoid systems, enabling precise genetic manipulation for disease modeling and therapeutic exploration. The platform's personalization capability stands out, as iPSCs can be derived from individual patients, creating patient-specific organoid models that better reflect the unique genetic and physiological characteristics of the individual. This allows for highly accurate modeling of human diseases and testing of drug responses, bridging the gap between preclinical and clinical studies. The organoids also exhibit a higher degree of human resemblance compared to traditional animal models, enabling more relevant efficacy and toxicity studies.

AccelBio's organoid models are available for different types of organs, each with varying complexity and disease modeling capabilities:

• Kidney Organoids (2.5D & 3D): These models replicate key structures of the kidney, including podocytes, proximal tubules, and distal tubules. They are disease-free under normal conditions but can be applied to study acute kidney injury or other kidney diseases upon request.

• Heart Organoids (3D): The heart models developed include various complexities, such as the ventricle myocardium organoids (MOs), coronary vascularized epicardium-myocardium organoids (cvEMOs), and sympathetic innervated epicardium-myocardium organoids (siEMOs). These models, without inherent disease phenotypes, can be tailored for studying adult cardiomyopathies, congenital heart diseases, and other cardiovascular disorders.

• Brain Organoids (2D & 3D): These models include a range of brain regions such as the forebrain (dorsal and ventral), midbrain (including dopaminergic neurons), and cerebellum. Although initially without disease phenotypes, these organoids are adaptable for studying neurodevelopmental disorders, such as Angelman Syndrome, or other brain-related diseases as needed.

These iPSC-based organoid models offer a more accurate and human-relevant approach to drug discovery (toxicity and efficacy studies), disease modeling, and personalized treatment strategies, enabling a deeper understanding of disease mechanisms and accelerating the development of effective therapeutics.

Furthermore, we are also available to develop organoid models for other organs, depending on project and partner needs.